In his more than 25-year career, Chris has become a recognized voice in the patient affordability and specialty medication arena, pioneering prominent copay and patient affordability programs, and creating innovative solutions for his clients.

A recognized leader in the space, Dowd has been on the forefront of virtually every development in the patient copay industry over the past decade.

Chris leads strategic market analysis and product go-to-market strategies at ConnectiveRx.

At Monument Advocacy, Joel runs the health practice and leads a seasoned team of government affairs professionals who have helped enact more than 50 laws over 19 years. With over three decades of experience in the healthcare policy and political arenas, Joel has been instrumental in helping Fortune 100 healthcare clients navigate complex public policy challenges and create opportunities for business growth.

Joel’s dedication to advancing healthcare reform is unmatched, having led various issue campaigns on reforming Medicare, improving SMB health coverage, lowering drug costs, improving medication adherence, and promoting healthcare transparency. He is a sought-after health policy expert, frequently speaking at national events, testifying before Congress, and producing high-profile policy summits and briefings featuring White House officials, Cabinet Secretaries, and Members of Congress. His thought leadership has been featured in major media outlets, including the Wall Street Journal, The New York Times, The Washington Post, Forbes, National Journal, Politico, and more.

He is a graduate of American University and dedicates his free time to community service and his family.

Dan joins the conversation with over 30 years of industry experience, focusing mainly on commercial biologic products, with expertise on both the medical and pharmacy sides.

He is currently the Executive Director of Access Services and Reimbursement at Regeneron, leading the access services and field reimbursement team, which includes all HUBs and field reimbursement teams across the portfolio.

In the past, he's also served in similar roles at top pharma organizations such as Fujisawa (Astellas), MedImmune (AZ), and  Auxilium (Endo).